Evaluation of efficacy of Berberine Ursodeoxycholate (HTD1801) compared to ongoing use of GLP-1 receptor agonists in patients with MASH and T2DM

被引：0
|
作者：
Harrison, Stephen A. [1 ]
Neff, Guy [2 ]
Gunn, Nadege [3 ]
Flyer, Abigail [4 ]
MacConell, Leigh [5 ]
机构：
[1] Pinnacle Clin Res, San Antonio, TX USA
[2] Covenant Metab Specialists, Sarasota, FL USA
[3] Impact Res Inst, Waco, TX USA
[4] Pacific Northwest Stat Consulting, Woodinville, WA USA
[5] HighTide Therapeut, Rockville, MD USA
来源：
JOURNAL OF HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
SAT-227
引用
收藏
页码：S614 / S615
页数：2
相关论文
共 50 条
  • [1] EVALUATION OF EFFICACY OF BERBERINE URSODEOXYCHOLATE (HTD1801) COMPARED TO ONGOING USE OF GLP-1 RECEPTOR AGONISTS IN PATIENTS WITH MASH AND T2DM
    Harrison, Stephen
    Neff, Guy
    Gunn, Nadege
    Flyer, Abigail
    MacConell, Leigh
    HEPATOLOGY, 2024, 80
  • [2] TIME COURSE OF ONSET, INCIDENCE AND PREVALENCE OF GASTROINTESTINAL ADVERSE EVENTS WITH HTD1801 (BERBERINE URSODEOXYCHOLATE) IN PATIENTS WITH MASH AND T2DM
    Neff, Guy
    Harrison, Stephen
    Gunn, Nadege
    Flyer, Abigail
    Liu, Kui
    Liberman, Alexander
    HEPATOLOGY, 2024, 80
  • [3] Time course of onset, incidence and prevalence of gastrointestinal adverse events with HTD1801 (Berberine Ursodeoxycholate) in patients with MASH and T2DM
    Neff, Guy
    Harrison, Stephen A.
    Gunn, Nadege
    Flyer, Abigail
    Liu, Kui
    Liberman, Alexander
    JOURNAL OF HEPATOLOGY, 2024, 80 : S618 - S618
  • [4] Efficacy of berberine ursodeoxycholate (HTD1801) in Chinese and Western patients with type 2 diabetes
    Gan, S.
    Ji, L.
    Ma, J.
    Cheng, Z.
    Gunn, N. T.
    Neff, G. W.
    Liu, K.
    MacConell, L.
    DIABETOLOGIA, 2024, 67 : S341 - S341
  • [5] Use of GLP-1 receptor agonists in patients with T2DM and chronic kidney disease
    Aldrich, Sarah
    Ashjian, Emily
    NURSE PRACTITIONER, 2019, 44 (03): : 20 - 28
  • [6] Efficacy and Safety of Cotadutide, a Dual GLP-1 and Glucagon Receptor Agonist in Patients with T2DM and DKD
    Parker, Victoria E.
    Hoang, Thuong
    Schlichthaar, Heike
    Gibb, Fraser W.
    Wenzel, Barbara
    Posch, Maximilian G.
    Chang, Yi-Ting
    Petrone, Marcella
    Hansen, Lars
    Ambery, Philip
    Heerspink, Hiddo L.
    Mccrimmon, Rory J.
    Jermutus, Lutz
    DIABETES, 2021, 70
  • [7] Treatment of Type 2 Diabetes mellitus (T2DM): Can GLP-1 Receptor Agonists fill in the gaps?
    Sharma, Smriti
    Bhatia, Vinayak
    CHEMICAL BIOLOGY LETTERS, 2020, 7 (04): : 215 - 224
  • [8] PSYCHOMETRIC EVALUATION OF THE NV QUESTIONNAIRE IN PATIENTS WITH T2DM RECEIVING A GLP-1 AGONIST
    McLeod, L.
    Sikirica, M., V
    Qin, S.
    Joshi, A., V
    Sweeney, C. T.
    Blum, S., I
    VALUE IN HEALTH, 2017, 20 (05) : A175 - A175
  • [9] Improvements in liver fibroinflammation (as assessed by corrected T1 [cT1]) with HTD1801 (berberine ursodeoxycholate) treatment in patients with non-alcoholic steatohepatitis and type 2 diabetes mellitus
    Harrison, Stephen
    Gunn, Nadege
    Neff, Guy
    Flyer, Abbey
    Liberman, Alexander
    MacConell, Leigh
    JOURNAL OF HEPATOLOGY, 2023, 78 : S653 - S654
  • [10] The Long-Term Efficacy and Safety of Canagliflozin in Combination with GLP-1 Receptor Agonist In Japanese Patients with T2DM
    Harashima, Shinichi
    Inagaki, Nobuya
    Kondo, Kazuoki
    Maruyama, Nobuko
    Otsuka, Makiko
    Kawaguchi, Yutaka
    Iijima, Hiroaki
    Goda, Maki
    Watanabe, Yumi
    DIABETES, 2017, 66 : A318 - A319
12345